|Home||» Products||» Gastrointestinal Drugs||» Daclatasvir dihydrochloride|
- Minimum Order Quantity
HEPCDAC Tablets are indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection in adults .
Limitations of Use
Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving HEPCDAC Tablets in combination with sofosbuvir for 12 weeks.
- Main Export Market(s)
- Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia